What are you looking for today?

Ordonio, Michaella B, Zaki, Randa Mohammed and Elkordy, Amal (2022) Dendrimers-Based Drug Delivery System: A Novel Approach in Addressing Parkinson’s Disease. Future Pharmacology, 2 (4). pp. 415-430.

Full text not available from this repository. (Request a copy)

Abstract

Abstract

Parkinson’s disease (PD) is a progressive neurodegenerative disease that is characterized
by the loss of dopamine. Since dopamine has trouble entering the blood–brain barrier, the utilization
of dendrimers and other nanomaterials is considered for conjugating the neurotransmitter and other
PD drugs. Dendrimers are three-dimensional, hyper-branched structures that are categorized into
several generations. Alpha-synuclein (ASN) is the protein involved in regulating dopaminergic
functions and is the main aggregate found inside Lewy bodies. Different types of dendrimers have
shown efficacy in disrupting the formation of unstable beta structures of ASN and fibrillation. The
conjugation of PD drugs into nanomaterials has elicited a prolonged duration of action and sustained
release of the drugs inside the BBB. The objectives of this study are to review the applications of a
dendrimer-based drug delivery system in addressing the root cause of Parkinson’s disease and to
emphasize the delivery of anti-Parkinson’s drugs such as rotigotine, pramipexole and dopamine
using routes of administration other than oral and intravenous.

Item Type: Article
Depositing User: Amal Elkordy
URI: https://sure.sunderland.ac.uk/id/eprint/15346

Further Details

More Information

Depositing User

Identifiers

Item ID
15346
Identification Number
doi.org/10.3390/futurepharmacol2040027

Users with ORCIDS

ORCID for Amal Elkordy

Catalogue record

Date Deposited
17 Oct 2022 12:25
Last Modified
04 Jun 2025 17:22

Contributors

Author
Michaella B Ordonio
Author
Randa Mohammed Zaki

University Divisions

Subjects

Actions (login required)

View Item (Repository Staff Only)